BioCryst director exercises options, sells 49,933 shares

BIOCRYST PHARMACEUTICALS INC director Theresa Heggie exercised stock options and sold shares on March 20, 2026.

Rhea-AI Filing Summary

BIOCRYST PHARMACEUTICALS INC director Theresa Heggie exercised stock options and sold shares on March 20, 2026. She exercised options for 49,933 shares of Common Stock at an exercise price of $6.30 per share and acquired the same number of shares.

She then sold 49,933 Common shares in an open-market transaction at a weighted average price of $10.11 per share, in multiple trades between $10.09 and $10.14. Following these transactions, she directly holds 65,352 shares of Common Stock.

Insider Trade Summary

Exercise and Sale: 49,933 shares ($190K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider HEGGIE THERESA

Role Director

Sold 49,933 shs ($505K)

Approx. gross sale proceeds $505K

Approx. exercise cost $315K

Approx. pre-tax spread $190K

Type	Security	Shares	Price	Value
Exercise	Automatic Stock Option Grant	49,933	$0.00	$0.00
Exercise	Common Stock	49,933	$6.30	$315K
Sale	Common Stock	49,933	$10.11	$505K

Holdings After Transaction: Automatic Stock Option Grant — 0 contracts (Direct); Common Stock — 65,352 shares (Direct)

Footnotes (1)

1. F1. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.09 to $10.14. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did BCRX director Theresa Heggie report?

Director Theresa Heggie exercised options to acquire 49,933 BioCryst shares and sold 49,933 Common shares on March 20, 2026. These trades were reported as a derivative exercise followed by an open-market sale, leaving her with 65,352 directly held shares.

How many BioCryst (BCRX) shares did Theresa Heggie sell?

Theresa Heggie sold 49,933 shares of BioCryst Common Stock. The sale was reported as an open-market transaction on March 20, 2026, following an option exercise for the same number of shares, and left her with 65,352 shares held directly afterward.

At what prices were Theresa Heggie’s BCRX shares sold?

Her BioCryst shares were sold at a weighted average price of $10.11 per share. According to the disclosure, individual sale prices ranged from $10.09 to $10.14, and full pricing details are available upon request from the company or the SEC staff.

What stock option exercise did BCRX director Theresa Heggie report?

She reported exercising an Automatic Stock Option Grant covering 49,933 underlying shares of BioCryst Common Stock at an exercise price of $6.30 per share. The option carried an expiration date of June 12, 2034, and was fully exercised in this transaction.

How many BioCryst (BCRX) shares does Theresa Heggie own after these transactions?

After completing the option exercise and subsequent sale, Theresa Heggie directly holds 65,352 shares of BioCryst Common Stock. Her total shares following the exercise before selling were 115,285, with 49,933 shares then sold in the open market on March 20, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/24/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HEGGIE THERESA

(Last) (First) (Middle)

4505 EMPEROR BOULEVARD

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/20/2026		M		49,933	A	$6.3	115,285	D
Common Stock	03/20/2026		S		49,933	D	$10.11(1)	65,352	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Automatic Stock Option Grant	$6.3	03/20/2026		M			49,933	06/12/2025	06/12/2034	Common Stock	49,933	$0	0	D

Explanation of Responses:

1. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.09 to $10.14. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

	/s/ Alane P. Barnes, by power of attorney	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)